These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 28651427)
1. Loeffler endocarditis in chronic eosinophilic leukemia with FIP1L1/PDGFRA rearrangement: full recovery with low dose imatinib. Kim DS; Lee S; Choi CW Korean J Intern Med; 2018 May; 33(3):642-644. PubMed ID: 28651427 [No Abstract] [Full Text] [Related]
2. Successful Heart Transplantation for Unreversible Endomyocardial Fibrosis Related to FIP1L1-PDGFRA Chronic Eosinophilic Leukemia. Fassnacht F; Roumier M; Fouret P; Levy V; Varnous S; Russel S; Lefevre G; Kahn JE Transplantation; 2015 Nov; 99(11):e176-7. PubMed ID: 26492057 [No Abstract] [Full Text] [Related]
3. Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript. Helbig G; Soja A; Świderska A; Hus M; Kyrcz-Krzemień S Leuk Lymphoma; 2016; 57(3):708-10. PubMed ID: 26430910 [No Abstract] [Full Text] [Related]
4. Oral mucosal manifestations of chronic eosinophilic leukaemia with FIP1L1-PDGFRα. Tsuda K; Tanimoto T; Hayakawa K; Komatsu T BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26759442 [No Abstract] [Full Text] [Related]
5. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome. Salemi S; Yousefi S; Simon D; Schmid I; Moretti L; Scapozza L; Simon HU Allergy; 2009 Jun; 64(6):913-8. PubMed ID: 19210352 [TBL] [Abstract][Full Text] [Related]
6. Detection of FIP1L1-PDGFRA fusion by FISH. Ma ES; Wong KF; Wong CL; Siu LL Br J Haematol; 2007 Aug; 138(3):279. PubMed ID: 17542982 [No Abstract] [Full Text] [Related]
7. [FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutant of PDGFRA gene: a case report and literature review]. Qu SQ; Wang Y; Sun XJ Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):159-61. PubMed ID: 23611226 [No Abstract] [Full Text] [Related]
8. Pure red cell aplasia associated with imatinib-treated FIP1L1-PDGFRA positive chronic eosinophilic leukemia. Tanaka H; Iwato K; Asou H; Kimura A Intern Med; 2010; 49(12):1195-200. PubMed ID: 20558942 [TBL] [Abstract][Full Text] [Related]
9. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Vandenberghe P; Wlodarska I; Michaux L; Zachée P; Boogaerts M; Vanstraelen D; Herregods MC; Van Hoof A; Selleslag D; Roufosse F; Maerevoet M; Verhoef G; Cools J; Gilliland DG; Hagemeijer A; Marynen P Leukemia; 2004 Apr; 18(4):734-42. PubMed ID: 14973504 [TBL] [Abstract][Full Text] [Related]
10. Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China. Qu SQ; Qin TJ; Xu ZF; Zhang Y; Ai XF; Li B; Zhang HL; Fang LW; Pan LJ; Hu NB; Xiao ZJ Oncotarget; 2016 May; 7(22):33229-36. PubMed ID: 27120808 [TBL] [Abstract][Full Text] [Related]
11. Maintenance therapy with imatinib appears necessary despite molecular remission in FIP1L1-PDGFRA fusion gene positive hypereosinophilic disorder. Ng HJ; Tan DC; Yiu RC; How GF Leuk Res; 2008 Jan; 32(1):169-71. PubMed ID: 17544504 [TBL] [Abstract][Full Text] [Related]
12. Rapid reversion of eosinophilic gastroenteritis associated with FIP1L1-PDGFRA fusion after targeted therapy with imatinib. Pitini V; Sturniolo G; Cavallari V; Arrigo C Br J Haematol; 2006 Jan; 132(2):123. PubMed ID: 16398645 [No Abstract] [Full Text] [Related]
13. Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity. Arai A; Yan W; Wakabayashi S; Hayashi S; Inazawa J; Miura O Int J Hematol; 2007 Oct; 86(3):233-7. PubMed ID: 17988989 [TBL] [Abstract][Full Text] [Related]
14. Imatinib Treatment of Lymphomatoid Papulosis Associated with Myeloproliferative Hypereosinophilic Syndrome Presenting the FIP1L1-PDGFRA Fusion Gene. García-Martínez P; Sitjas D; Llistosella E; Espinet B; Rodríguez-Rivera M; Hernandez-Muñoz M; Gallardo F; Pujol RM Acta Derm Venereol; 2017 Jul; 97(7):855-857. PubMed ID: 28374041 [No Abstract] [Full Text] [Related]
16. FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia. Cools J Verh K Acad Geneeskd Belg; 2005; 67(3):169-76. PubMed ID: 16089297 [TBL] [Abstract][Full Text] [Related]
17. Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing. Klion AD; Robyn J; Maric I; Fu W; Schmid L; Lemery S; Noel P; Law MA; Hartsell M; Talar-Williams C; Fay MP; Dunbar CE; Nutman TB Blood; 2007 Nov; 110(10):3552-6. PubMed ID: 17709602 [TBL] [Abstract][Full Text] [Related]
18. Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome. Helbig G; Kyrcz-Krzemień S Am J Hematol; 2014 Jan; 89(1):115. PubMed ID: 24009127 [No Abstract] [Full Text] [Related]